MedPath

Efficacy of adjunctive cerebellar HD-tDCS on craving in Alcohol Dependence Syndrome.

Not Applicable
Conditions
Health Condition 1: F102- Alcohol dependence
Registration Number
CTRI/2023/03/051030
Lead Sponsor
Central Institute of Psychiatry
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Subjects diagnosed with mental and behavioral disorders due to use of alcohol, dependent syndrome,currently using the substance (F10.24) as per International Classification of disease 10th (ICD-10, DCR) Diagnostic Criteria for Research.

2.Age between 18-50 years

3.Ready to give informed consent

4.Right-handed

5.Educated up to class VIII or above

6.Clinical institute withdrawal assessment for alcohol revised (CIWA-AR) protocol score less than 10.

Exclusion Criteria

1.Subject having alcohol related complicated withdrawal.

2.Any comorbid substance use disorder except nicotine and caffeine.

3.Participants with hepatic derangements or impaired liver function test (LFT).

4.Patients with metal in cranium, pacemaker, history of significant traumatic brain injury; history of epilepsy and cerebrovascular accident(CVA); skin problems such as dermatitis, psoriasis, or eczema over the scalp.

5.Participants having any contraindications for undergoing HDtDCS and fMRI study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Reduction in scores of cravings as rated by Alcohol Craving Questionnaire (ACQ) and Obsessive-Compulsive Drinking Scale (OCDS) after 2 and 4 weeks of HDtDCS treatment.Timepoint: Reduction in scores of cravings as rated by Alcohol Craving Questionnaire (ACQ) and Obsessive-Compulsive Drinking Scale (OCDS) after 2 and 4 weeks of HDtDCS treatment.
Secondary Outcome Measures
NameTimeMethod
Changes in cue based BOLD activation as measured by fMRI after 2 and 4 weeks of HDtDCS treatment.Timepoint: Changes in cue based BOLD activation as measured by fMRI after 2 and 4 weeks of HDtDCS treatment.
© Copyright 2025. All Rights Reserved by MedPath